PLRX Stock Forecast: Pliant Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.60
−4.02% on the day

The median 12-month analyst price target for Pliant Therapeutics, Inc. is $2. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 68 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$36.9M
Ticker Nerd rank
68/ 100
Median analyst target
$2.00
Analysts covering
4
Revenue$0.0
Operating income−$23.9M
Net income−$22.4M
Free cash flow−$12.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.6%
1M
−34.7%
YTD
−51.2%
1Y
−61.9%
From 52W high
−63.0%
From 52W low
0.0%
$0.60
$1.61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pliant Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
68/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
89
Growth
86
Accruals
83
Volatility
81
Quality
56
Value
31
Revisions
31
Momentum
15

Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PLRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26PLRXHigh $2.00Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
0
Buy
3
Hold
1
Sell
$2.00
Low
$2.00
Median
$2.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Mar 2026Canaccord GenuityMaintainsHold$4.00 → $3.00
12 Mar 2026Piper SandlerMaintainsOverweight$4.00 → $3.00
7 Nov 2025RBC CapitalMaintainsSector Perform—
10 Oct 2025JP MorganDowngradeUnderweight—
8 Aug 2025Piper SandlerMaintainsOverweight—
18 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
4 Mar 2025Cantor FitzgeraldReinstatesNeutral—
4 Mar 2025CitigroupMaintainsNeutral—
4 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
4 Mar 2025NeedhamDowngradeHold—
4 Mar 2025RBC CapitalMaintainsSector Perform—
4 Mar 2025Wells FargoMaintainsEqual-Weight—
3 Mar 2025Leerink PartnersDowngradeMarket Perform—
14 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
14 Feb 2025NeedhamReiteratesBuy—
10 Feb 2025Canaccord GenuityDowngradeHold—
10 Feb 2025CitigroupDowngradeNeutral—
10 Feb 2025HC Wainwright & Co.DowngradeNeutral—
10 Feb 2025JP MorganDowngradeNeutral—
10 Feb 2025NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PLRX.

Market Radar

This page is one stock. Monday covers all of them.

PLRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PLRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pliant Therapeutics, Inc. returned −61.9% against +6.9% for the S&P 500, dividends included.

PLRX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26PLRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.2×

Cheaper than 94% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−50.3%

Higher than 22% of US stocks

Return on assets
−23.3%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pliant Therapeutics, Inc. has a market value of $36.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$92.3M.

  • Diluted earnings per share, trailing twelve months: −$1.49.

  • Free cash flow in the twelve months to 30 June 2026: −$70.9M.

  • Shares outstanding: 61.9M.

  • Pliant Therapeutics, Inc. employs 49 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

PLRX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PLRXPliant Therapeutics, Inc.$36.9M68
CNTBConnect Biopharma Holdings Ltd.$37.1M45
GRCEGrace Therapeutics, Inc.$36.0M44
TILInstil Bio, Inc.$35.5M48
CUECue Biopharma, Inc.$34.7M20
DWTXDogwood Therapeutics, Inc.$39.6M71
INKTMiNK Therapeutics, Inc.$39.8M62

Take a look at PLRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pliant Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PLRX

What is the PLRX stock price forecast for 2026-2027?

The median 12-month analyst price target for Pliant Therapeutics, Inc. is $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PLRX stock a buy right now?

Of the 4 analysts covering Pliant Therapeutics, Inc., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pliant Therapeutics, Inc. 68 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLRX?

As at 21 Nov 2026, Pliant Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).

Will PLRX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $2, and Ticker Nerd's factor model ranks Pliant Therapeutics, Inc. 68 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PLRX stock forecast for 2030?

No analyst covering Pliant Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has PLRX stock performed over the past year?

Pliant Therapeutics, Inc. returned -61.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pliant Therapeutics, Inc. do?

Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions. The company’s current pipeline centers on oral and other targeted drug candidates designed to modulate key pathways involved in fibrosis, with programs being studied in areas such as idiopathic pulmonary fibrosis, primary sclerosing cholangitis, liver fibrosis, solid tumors, and muscular dystrophies.

Company

About Pliant Therapeutics, Inc.

Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions. The company’s current pipeline centers on oral and other targeted drug candidates designed to modulate key pathways involved in fibrosis, with programs being studied in areas such as idiopathic pulmonary fibrosis, primary sclerosing cholangitis, liver fibrosis, solid tumors, and muscular dystrophies. Its research platform is built around integrin biology, which plays an important role in cell signaling, tissue remodeling, and disease progression. Pliant Therapeutics Inc. operates as a specialist developer within the biotechnology sector, contributing to the broader market for treatments aimed at serious, chronic, and often underserved diseases.

CEO Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D. · 49 employees · United States · https://pliantrx.com